Photodynamic therapy in gynaecological neoplastic diseases.

Since 1982, our department has used photodynamic therapy (PDT) in the treatment of loco-regional recurrences of gynaecological cancers. We have treated 26 patients in this time. In the majority of cases the site of vaginal recurrences was the vaginal vault. The light sources were an Argon-dye laser (Meditec) and, in some cases, a CO2 laser. The light dose ranged between 60 and 500 J cm-2. The photosensitizing drug used was Hematoporphyrin (HP) (Monico Farmaceutici) at the dose of 5 mg kg-1 body weight. Patients were evaluated 45 days after the treatment with a gynaecological examination and after 75-90 days with a vaginal smear. The results were divided into 2 groups: objective and symptomatic. The symptomatic response concerned only the patients treated with a palliative aim and, in this case, a complete response (CR) was a complete absence of symptoms at least for 60 days. In this group the complete response rate was 66%. In the curative group, the complete response was a cytological and/or histological absence of lesions. In this group we had 12 CR (70.58%). The survival rate was also evaluated. A significant review of the photodynamic therapy in gynaecological neoplasms has also been done.

[1]  D. Minucci,et al.  RECURRING GYNAECOLOGIC CANCER TREATED WITH PHOTODYNAMIC THERAPY , 1987, Photochemistry and photobiology.

[2]  Huang Jg.  [Photodynamic therapy for genitourinary carcinomas--report of 26 tumors in 17 patients]. , 1991 .

[3]  D. Harris,et al.  Photodynamic Therapy for Cancer of the Lower Female Genital Tract , 1986 .

[4]  B. Ward,et al.  The treatment of vaginal recurrences of gynecologic malignancy with phototherapy following hematoporphyrin derivative pretreatment. , 1982, American journal of obstetrics and gynecology.

[5]  D. Alberts,et al.  A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. , 1990 .

[6]  B W Henderson,et al.  Hyperthermic potentiation of photodynamic therapy employing photofrin I and II: Comparison of results using three animal tumor models , 1987, Lasers in surgery and medicine.

[7]  E. Land,et al.  Porphyrin localization and treatment of tumors , 1985, British Journal of Cancer.

[8]  T. Baglioni.  Elementi di Radiobiologia , 1962 .

[9]  H. Schellhas,et al.  Photodynamic therapy of gynecologic neoplasms after presensitization with hematoporphyrin derivative , 1985, Lasers in surgery and medicine.

[10]  J. Meigs.  Cancer of the Female Genitalia , 1929 .

[11]  A. Kuten,et al.  Correlations of dose and time-dose-fractionation factors (TDF) with treatment results and side effects in cancer of the uterine cervix. , 1986, Gynecologic oncology.

[12]  J. Mikuta,et al.  Results of radiation therapy given after radical hysterectomy , 1982, Cancer.

[13]  T. Dougherty,et al.  Lasers and hematoporphyrin derivative in cancer , 1983 .

[14]  C. Marth,et al.  Photodynamische Therapie bei Patientinnen mit Rezidiven gynäkologischer Karzinome , 1993 .

[15]  P. Grigsby,et al.  Outcome of recurrent cervical carcinoma following definitive irradiation. , 1989, Gynecologic oncology.

[16]  H. Takamizawa,et al.  Experimental studies of photoradiation therapy (PRT) against human uterine cancer cell line , 1984 .

[17]  L. Brady,et al.  Failure patterns in gynecologic cancer. , 1986, International journal of radiation oncology, biology, physics.

[18]  A. Berchuck,et al.  Pelvic exenteration: factors associated with major surgical morbidity. , 1989, Gynecologic oncology.